Anima Biotech
mRNA Translation Treatments
Company Name | Updating Date | Neurotech Category | Market Category | Target Market | Technologies | Company Founded Year | Company Number of Employees |
|---|---|---|---|---|---|---|---|
Anima Biotech | 02/07/2022 | NeuroPharmacology | NeuroBioTechnology | Biotechnology & Biopharmaceutical | Medical use (pharma, nerve damage rehabilitation, neurodiagnostics. inc. early diagnosis) | Biochemical: pharmacological drugs (Developing drugs) | 01/01/2014 | "51-200" |
Anima Biotech is advancing Translation Control Therapeutics, a platform for the discovery of small-molecule drugs that specifically control mRNA translation as a new strategy against hard and undruggable targets in many diseases.
Anima's proprietary technology enables visualization and monitoring of target protein translation via pulses of light emitted by ribosomes. The fully automated high-throughput screening system discovers small molecules that modulate the light as they decrease or increase the target protein's production. The platform integrates proprietary technologies in biology, bioinformatics, image analysis, big data analysis, and artificial-intelligence algorithms in a cloud-computing software architecture.
Anima develops a pipeline across therapeutic areas and partners with pharmaceutical companies for their targets, including a collaboration with Lilly for the discovery and development of translation inhibitors of several targets. The company has 5 granted patents, 14 peer-reviewed publications, and 17 scientific collaborations.